LBA
PROF

Letko, Brosseau & Associates’s Profound Medical PROF Stock Holding History

Letko, Brosseau & Associates’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.4M Sell
935,725
-17,450
-2% -$117K 0.08% 72
2026
Q1 		$6.09M Sell
953,175
-17,500
-2% -$121K 0.1% 67
2025
Q4 		$7.63M Sell
970,675
-15,575
-2% -$100K 0.12% 65
2025
Q3 		$4.82M Sell
986,250
-218,000
-18% -$1.11M 0.08% 65
2025
Q2 		$7.15M Sell
1,204,250
-3,600
-0.3% -$19K 0.14% 65
2025
Q1 		$5.92M Sell
1,207,850
-3,300
-0.3% -$22.8K 0.13% 64
2024
Q4 		$8.69M Buy
1,211,150
+12,375
+1% +$95K 0.17% 68
2024
Q3 		$9.55M Hold
1,198,775
– – 0.17% 69
2024
Q2 		$10.1M Sell
1,198,775
-32,650
-3% -$263K 0.19% 72
2024
Q1 		$9.95M Buy
1,231,425
+53,575
+5% +$447K 0.17% 71
2023
Q4 		$9.46M Buy
1,177,850
+13,725
+1% +$130K 0.17% 70
2023
Q3 		$11.4M Sell
1,164,125
-4,150
-0.4% -$43K 0.22% 70
2023
Q2 		$15M Sell
1,168,275
-3,500
-0.3% -$43.4K 0.28% 70
2023
Q1 		$10.9M Sell
1,171,775
-8,650
-0.7% -$100K 0.2% 72
2022
Q4 		$12.6M Sell
1,180,425
-75,250
-6% -$410K 0.23% 78
2022
Q3 		$5.01M Buy
1,255,675
+650
+0.1% +$4.39K 0.1% 78
2022
Q2 		$8.89M Sell
1,255,025
-44,100
-3% -$349K 0.16% 77
2022
Q1 		$11.7M Buy
1,299,125
+476,875
+58% +$4.59M 0.17% 76
2021
Q4 		$9.28M Buy
822,250
+4,275
+0.5% +$53.4K 0.13% 78
2021
Q3 		$11.9M Buy
817,975
+6,900
+0.9% +$105K 0.17% 77
2021
Q2 		$13.2M Sell
811,075
-8,825
-1% -$164K 0.18% 75
2021
Q1 		$16.4M Sell
819,900
-19,800
-2% -$475K 0.22% 73
2020
Q4 		$17.3M Buy
839,700
+793,700
+1,725% +$14.6M 0.24% 70
2020
Q3 		$811K Buy
+46,000
New +$731K 0.01% 86

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $349M AUM 28.06% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
RMC
Ring Mountain Capital Tiburon, California $238M AUM 61.63% 1-Year Est. Return

Letko, Brosseau & Associates's PROF Position: Q2 2026 in Review

Letko, Brosseau & Associates reduced its Profound Medical (PROF) stake by 1.8% in Q2 2026, selling an estimated $117K and leaving 935,725 shares worth $5.4M. The position accounts for 0.08% of the portfolio, ranked #72.

Letko, Brosseau & Associates first reported a position in PROF in Q3 2020 and has held it in 24 quarters since. The position peaked at $17.3M in Q4 2020. 56 funds tracked by Wall St. Rank hold PROF as of Q2 2026.

  • Letko, Brosseau & Associates held 935,725 shares of Profound Medical worth $5.4M as of Q2 2026.
  • Letko, Brosseau & Associates sold 17,450 Profound Medical shares in Q2 2026, an estimated $117K.
  • Profound Medical made up 0.08% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #72 holding.
  • Letko, Brosseau & Associates first reported a position in Profound Medical in Q3 2020 and has held it in 24 quarters since.
  • Letko, Brosseau & Associates's Profound Medical position peaked at $17.3M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Profound Medical as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.